Compare Neurocrine Biosciences Inc (NBIX) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Stitch Fix Inc — how do they compare? Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B), while Stitch Fix Inc trades at $3.79 (market cap $530.37M). The key difference: Neurocrine Biosciences Inc is far larger — about 31.6× Stitch Fix Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SFIX | |
|---|---|---|
Market Cap | $16.76B | $530.37M |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $5.83 |
52-Week Low | $123.10 | $3.06 |
Enterprise Value | $16.78B | $418.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Stitch Fix (SFIX) trades at $4.20, up 4.22% today, showing stabilization after a multi-year decline. The stock is technically bullish with strong moving average signals, while fundamentals reflect a turnaround with revenue stabilizing at $1.27B and net losses narrowing to -$28.74M in 2025. Recent news highlights AI-driven personalization gains and a debt-free balance sheet, supporting a potential recovery narrative.
The outlook hinges on execution of the turnaround; improving client growth and cost controls offer upside, but persistent losses and consumer spending pressures pose risks. Analysts are cautious with a $4.75 price target and 63.6% hold rating, suggesting the stock may be fairly valued amid its recovery phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
